The targeting construct to generate a Flvcr1a floxed allele, was designed as follows: the first exon of Flvcr1a gene was flanked with loxP sites and the neomycin resistance gene, flanked with Flippase Recognition Target (FRT) sites to permit its excision, was inserted in the first intron. ;alb-cre mice.
debris and non-parenchymal cells were carefully pipetted out and discarded. Then, the lowest layer that contains the live hepatocytes was collected. Cells were washed, centrifuged and then plated onto collagen-coated well plates. Primary hepatocytes were treated with 5mM ALA or 5mM ALA plus 0.5mM Succynilacetone for 30 minutes for heme uptake experiments or for 8 hrs for ROS production assay.
FLVCR1a-overexpressing HepG2 Cell Line
HepG2 cells were transduced with a lentiviral vector carrying the human Flvcr1a cDNA fused to the Myc epitope to obtain a cell line overexpressing the Flvcr1a-Myc protein. Control HepG2 cells were transduced with a control lentiviral vector. For localization experiments, we performed immunofluorescence on overexpressing and control HepG2 cells using the cell membrane marker WGA (Life Technologies), an antibody against Myc (produced in our laboratory) and one against ZO-1 (Life Technologies).
Heme Content
Heme content in tissues and in bile samples was quantified fluorometrically by the method of Sassa (5) . Briefly, tissues were homogenized in phosphate buffer saline (PBS) and protein content was determined by using the Bio-Rad protein assay system (Bio-Rad, Munchen, Germany). Ten g of protein samples were incubated with 0.5 ml of 2 M Oxalic Acid (SigmaAldrich, Milano, Italy) at 95°C for 30 min. Samples were subsequently centrifuged at 14000 rpm for 5 min. Fluorescence emission in the supernatant was determined spectrofluorimetrically (Glomax, Promega Italia). Excitation and emission wavelengths were set at 405 and 662 nm, respectively. The background was evaluated by measuring fluorescence in non-boiled samples. A standard curve of hemin was run in parallel. Using this method, heme content was measured in primary hepatocytes, total liver extract and hepatic cytosolic and microsomal fractions.
Tissue Iron Measurement
Tissue non-heme iron content determined with a colorimetric method using 4,7-diphenyl-1, 10-phenantroline disulphonic acid (BPS) as chromogen (6) . Briefly, 0.1 g of dry tissue was incubated overnight in a mixture of trichloroacetic (10%) and hydrochloric (4N) acids, and 100 l of supernatant reduced with thioglycolic acid (Sigma-Aldrich) and acetic acid-acetate buffer (pH4.5). Ferrous iron content was determined spectrophotometrically at 535 nm following addition of BPS and incubation for 1 hr at 37ºC. Results were expressed as g iron/g dry tissue weight.
HO Activity Assay
HO activity was measured by spectrophotometric determination of bilirubin produced from hemin added as the substrate (1) . Liver samples were lysed with a hypotonic buffer (0.1 M potassium phosphate, 2mM MgCl 2 , Complete Protease Inhibitor Cocktail, Roche Diagnostics Corp., Milano, Italy, pH 7.4) for 15' on ice. After brief sonication. 0.6 M sucrose was added to cell lysates in order to obtain an hysotonic solution (final 0.25 M sucrose). Lysates were centrifuged at 1000 x g for 10 min at 4°C to pellet nuclei, and supernatants centrifuged at 12000 x g for 15 min at 4 °C to pellet mitochondria. Finally, supernatants were ultracentrifuged at 105000 x g for 1 hour at 4°C. Microsomal fractions were resuspended in 100 mM potassium phosphate buffer pH 7.4, containing 2 mM MgCl 2 and Complete protease inhibitor. Protein concentration was determined using a small aliquot of these suspensions (Bio-Rad, Munchen, Germany). The microsomal supernatant fraction (cytosol) from the liver of a normal rat served as source of biliverdin reductase. Liver supernatant was prepared fresh from rat liver by homogenization in 0.1 M sodium citrate buffer, pH 5, containing 10% glycerol. HO-1 activity assay was carried out by incubating 600 g microsome proteins with a reaction mixture containing 1 mM NADPH, 2 mM glucose-6-phosphate, 1U glucose-6-phosphate dehydrogenase (Sigma-Aldrich), 25 M hemin, 2 mg of rat-liver cytosol and 100 mM potassium phosphate buffer, pH 7.4 (400 l final volume). The reaction was conducted in the dark for 1h at 37 °C and terminated by placing tubes on ice for 2 min. The amount of bilirubin was determined by the difference in absorption between 464 and 530 nm (extinction coefficient, 40 mM -1 cm -1 for bilirubin). HO activity was expressed in picomoles of bilirubin formed per milligram microsomal protein per hour.
Bilirubin concentration in bile
Direct and Total bilirubin concentrations in bile were determined colorimetrically using the QuantiChrom bilirubin assay kit DIBR-180 from BioAssay Systems (Hayward, CA). For bile collection, an upper midline laparotomy was realized, the cystic duct was ligated and transected and a cholecystectomy performed. Gallbladder was removed and its volume was determined by water displacement. Bile was collected and stored at -20°C until analysis (1).
Lipid Peroxidation Assay
Lipid peroxidation from tissue extracts was measured using the colorimetric assay kit Bioxytech LPO-586 from Oxis International (Portland, OR), according to the manufacturer's instructions.
Measurement of intracellular ROS accumulation
Accumulation of ROS in primary hepatocytes was assessed by using the oxidant-sensitive 
ALAS Activity Assay
d -ALAS activity in the liver was assayed according to the methods of Marver et al. (7) with minor modification. Briefly, the livers were washed in cold saline, minced, and homogenized in 3 volumes of cold 10 mM Tri-HCl buffer, pH 7.4, containing 0.9% NaCl and 0.05 mM EDTA. A 16-ml reaction mixture consisting of 4 ml of 240 mM Tris-HCl, pH 8.0, 2 ml of 80 mM EDTA, 2 ml of 800 mM glycine, and 8 ml of liver homogenate was incubated for 1 h at 37°C. Reactions were terminated by adding 4 ml of 12.5% trichloroacetic acid solution, and the samples were centrifuge d at 140 3 g for 10 min. The supernatant was further centrifug ed at 10,000 3 g for 10 min. To 16 ml of the resultant supernata nt, 0.8 ml 2.5 N NaOH, 16 ml 1 M sodium acetate buffer, pH 4.6, and 0.8 ml of acetylace tone were added, and then the mixture solution was heated in boiling water for 20 min. After cooling at ambient temperatures, the sample solution was applied to a Dowex 1-X8 resin (Muromachi Chemicals, Kyoto, Japan) column (3 ml). The column was washed with 15 ml of water, 12 ml of 50% methanol in water, and 12 ml of 1 M acetic acid solution, and then eluted with glacial acetic acid. A first run (1 ml) of the elution was discarded , and the subsequen t eluent (3 ml) was collected . To each fraction, the same volume of Ehrlich' s reagent was added, and the mixture solution was allowed to stand for 20 min at room temperature. The resultant reactant of d -aminolevulinic acid was spectrophotometrically measured at 553 nm.
CYP1A1 Activity Assay
CYP1A1 activity was assessed by measuring Ethoxyresorufin-O-deethylase (EROD) activity in liver microsomes using 7-ethoxyresorufin as a substrate (8) . Liver microsomes (120 μg protein)
were added to a reaction mixture of 0.1 M potassium phosphate buffer (pH 7.4) and 1.5 M 7-ethoxyresorufin. The reaction was started by the addition of 0.5 mM nicotinamide adenine dinucleotide phosphate (NADPH) in a final volume of 1 mL. After incubation at 25°C for 5 min, increase in fluorescence was recorded with excitation and emission wavelengths fixed at 535 nm and 585 nm, respectively. ;albcre mice, n=4 (bottom). Unpaired T-test analysis with Welch's correction was performed on data reported in Figure S1D ;alb-cre mice upon acute heme overload. After treatment bile was collected from the gallbladder and heme was quantified according to the method described in supplemental method section. After acute heme overload no difference in bile heme content was observed between ;alb-cre mice, without any remarkable difference. n=6. Two-way ANOVA with Bonferroni post-test analysis was performed on data reported here. (B) Representative images of an immunofluorescence on human hepatocarcinoma HepG2 cells overexpressing Flvcr1a-Myc protein. Cells were stained with DAPI for nuclei identification, an anti-Myc antibody for Flvcr1a-Myc staining and WGA, a dye specific for membranes. Together these results suggest that FLVCR1a localizes at the hepatic sinusoidal membrane. This needs to be confirmed in vivo when a specific antibody for mouse FLVCR1a will be available.
CYP2E1 Activity Assay

FLVCR1a deficiency does not affect the response to PHZ-induced hemolysis
We did not observe any difference in heme and iron content ( Figure S5A ;alb-cre mice is blocked by co-treatment with both heme synthesis inhibitors, acting at different levels along the heme biosynthetic pathway. n=6. Two-way ANOVA with Bonferroni post-test analysis was performed on data reported in this figure. ;alb-cre mice ( Figure S10E ). As expected, Cyp2e1 mRNA level in Imidazole-treated animals was not increased since the expression of this gene is mainly regulated at post-transcriptional level ( Figure S10D ).
These results strengthen those obtained with Dexamethasone or Be(a)P treatment, suggesting that the lack of Flvcr1a affects the activity of a wide range of cytochromes. ;alb-cre mice as well as CYP1A1 and CYP3A expression, as shown in Figure 7D .
Supplemental legend for Figure7F
Figure 7F. Cartoon showing FLVCR1a mood of action in the liver.Upon steady state condition (left), heme is synthesized by ALAS1 and enters the free heme pool, in which it is dinamically exchanged between the regulatory and the active pool contained in hemoproteins. The heme pool is maintained by a balance between heme synthesis, degradation and export thanks to the coordinated activity of ALAS1, HO1 and FLVCR1a. This ensures a proper size of the heme pool that reflects the functionality of the major group of hepatic hemoproteins, cytochromes P450. The deletion of the heme exporter FLVCR1a (right) alters intracellular heme homeostasis, thus impairing this balance. The enhacement in heme pool size due to the lack of heme export causes, on the one hand, the compensatory upregulation of HO1 and, on the other, the compensatory inhibition of ALAS1. This leads to an increase in heme degradation and a decrease in de novo heme synthesis, thus resulting in impaired CYP450 expression and activity.
